HEALTH TECHNOLOGY

NVIDIA Launches UK’s Most Powerful Supercomputer, for Research in AI and Healthcare

NVIDIA | July 07, 2021

NVIDIA today officially launched Cambridge-1, the United Kingdom’s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country’s world-leading life sciences industry.


Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs and improving the accuracy of finding disease-causing variations in human genomes.


Cambridge-1 brings together decades of NVIDIA’s work in accelerated computing, AI and life sciences, where NVIDIA Clara™ and AI frameworks are optimized to take advantage of the entire system for large-scale research. An NVIDIA DGX SuperPOD™ supercomputing cluster, it ranks among the world’s top 50 fastest computers and is powered by 100 percent renewable energy.


“Cambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life’s work on the U.K.’s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the U.K.,” said Jensen Huang, founder and CEO of NVIDIA. “The discoveries developed on Cambridge-1 will take shape in the U.K., but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.”
Cambridge-1 builds on the U.K.’s status as a global leader in life sciences, technology and AI by providing advanced infrastructure for current and future generations to carry out groundbreaking research within the country.


According to a report by Frontier Economics, an economics consulting firm, Cambridge-1 has the potential to create an estimated value of £600 million (about $825 million) over the next 10 years.


AstraZeneca: Transforming Drug Discovery with AI


NVIDIA is collaborating with AstraZeneca to fuel faster drug discoveries by creating a transformer-based generative AI model for chemical structures. Transformer-based neural network architectures, which have become available only in the last several years, allow researchers to leverage massive datasets using self-supervised training methods, avoiding the need for manually labeled examples during pre-training.


The MegaMolBART drug discovery model is being used in reaction prediction, molecular optimization and de novo molecular generation and will optimize the drug development process. It is based on AstraZeneca’s MolBART transformer model and is being trained on the ZINC chemical compound database — using NVIDIA’s Megatron framework to enable massively scaled-out training on supercomputing infrastructure. This open-source model will be available to researchers and developers in the NVIDIA NGC™ software catalog.


NVIDIA and AstraZeneca have a separate project on Cambridge-1 focused on the use of AI in digital pathology. In digital pathology, significant time and money are spent annotating whole slide images of tissue samples, to aid the search for new insights. By using unsupervised AI algorithms trained on thousands of images, it is possible to remove the process of annotating while simultaneously finding potential imaging features that correlate with drug response.


“Training AI algorithms on whole slide images is challenging in part due to the size of the images,” said Lindsay Edwards, vice president of Data Science and AI, Respiratory and Immunology, BioPharmaceuticals R&D at AstraZeneca. “Working with NVIDIA on Cambridge-1 enables us to scale our current work and develop new methodologies advancing the use of AI in digital pathology.”


GSK: Steering Great Science with Partners for Patients


GSK’s research and development approach includes a focus on genetically validated targets, which are twice as likely to become medicines and now make up more than 70 percent of its research pipeline. To maximize the potential of these insights, GSK has built state-of-the-art capabilities at the intersection of human genetics, functional genomics, and artificial intelligence and machine learning.


“Advanced technologies are core to GSK’s R&D approach and help to unlock the potential of large, complex data through predictive modeling at new levels of speed, precision and scale,” said Dr. Kim Branson, senior vice president and global head of AI-ML at GSK. “We are pleased to have the opportunity to partner with NVIDIA to deliver on GSK’s drug discovery ambition and contribute to the U.K.’s rich life sciences ecosystem — both aims that have patient benefit at the centre.”


Working with partners at the cutting edge of genetics, genomics and AI/ML can ultimately help GSK predict more about human health, and develop better medicines that are twice as likely to succeed in the clinic and go on to become approved therapies that benefit patients. Access to Cambridge-1 will contribute additional computational power and state-of-the-art AI technology to GSK’s drug discovery process.


King’s College London & Guy’s and St Thomas’ NHS Foundation Trust: AI-Generated Synthetic Brain Data


King’s College London and Guy’s and St Thomas’ NHS Foundation Trust are using Cambridge-1 to teach AI models to generate synthetic brain images by learning from tens of thousands of MRI brain scans, from various ages and diseases. The ultimate goal is to use this synthetic data model to gain a better understanding of diseases like dementia, stroke, brain cancer and multiple sclerosis and enable earlier diagnosis and treatment.


As this AI synthetic brain model can generate an infinite amount of never-seen brain images with chosen characteristics (age, disease, etc.), it will allow a better and more nuanced understanding of what diseases look like, possibly enabling an earlier and more accurate diagnosis.


“Through this partnership, we will be able to use a scale of computational power that is unprecedented in healthcare research,” said Professor Sebastien Ourselin, head of the School of Biomedical Engineering & Imaging Sciences at King’s College London. “It will be truly transformational for the health and treatment of patients.”


This research leverages several of the U.K.’s world-leading healthcare resources through close collaboration with the National Health Service and the UK Biobank, one of the richest biomedical databases in the world. King’s College London intends to share this synthetic data model with the greater research and startup community.


“The power of artificial intelligence in healthcare will help to speed up diagnosis for patients, improve services such as breast cancer screening, and support the way that we risk assess and prioritize patients according to clinical need,” said Professor Ian Abbs, chief executive officer of Guy’s and St Thomas’ NHS Foundation Trust. “We are excited about our involvement in the Cambridge-1 data center as it will enable us to be amongst the first to benefit from these new AI capabilities — using the very latest technology to benefit our patients, as well as manage precious resources more efficiently.”


Oxford Nanopore: Scalable, Real-Time Genomics


Oxford Nanopore Technologies’ long-read sequencing technology is being used in more than 100 countries to gain genomic insights across a breadth of research areas — from human and plant health to environmental monitoring and antimicrobial resistance.


Oxford Nanopore deploys NVIDIA technology in a variety of genomic sequencing platforms to develop AI tools that improve the speed and accuracy of genomic analysis. With access to Cambridge-1, Oxford Nanopore will be able to carry out tasks relating to algorithm improvement in hours rather than days. These improved algorithms will ensure improved genomic accuracy for greater insights and quicker turnaround times in scientists’ hands.


“Harnessing the power of Cambridge-1 will help us further speed up our algorithm development to support powerful, accurate genomic analysis,” said Rosemary Sinclair Dokos, vice president of Product and Programme Management at Oxford Nanopore. “This will in turn enable the scientists using our technology on the ground to gain more insights than ever before, across a breadth of research areas.”


About Cambridge-1
Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.


About NVIDIA
NVIDIA’s (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company’s pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others. 

Spotlight

Many health plans utilize clinical analytics to guide their business decisions and the vast majority intend to outsource their analytics-related projects by the beginning of 2017. See how health care organizations are using predictive analytics in practice, as an underlying support to their population health management efforts.

Spotlight

Many health plans utilize clinical analytics to guide their business decisions and the vast majority intend to outsource their analytics-related projects by the beginning of 2017. See how health care organizations are using predictive analytics in practice, as an underlying support to their population health management efforts.

Related News

HEALTH TECHNOLOGY

Vicarious Surgical Announces Center of Excellence Agreements with HCA Healthcare and UH Ventures to Advance System Design

Vicarious Surgical Inc. | July 08, 2022

Vicarious Surgical Inc. a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it has signed collaborative Center of Excellence agreements with both HCA Healthcare, one of the nation’s leading providers of healthcare services comprising 182 hospitals, and University Hospitals Ventures, the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with more than 20 hospitals, over 50 health centers, and over 200 physician offices in northern Ohio. As part of these agreements, HCA Healthcare and UH Ventures will each provide user input through their system physicians as the Company advances the design of its Vicarious Surgical Robot. Through these distinct collaborations, Vicarious Surgical will gain unique exposure to the detailed surgical workflows at each of these partners and incorporate direct surgeon and administrator feedback into its total product ecosystem to meet the needs of major US hospital systems. Additionally, clinical and human-centered design experts from both HCA Healthcare and UH will assist Vicarious Surgical to further enhance product design, helping ensure readiness for streamlined adoption upon FDA Approval. “Establishing our Center of Excellence model with two leading U.S. health systems offers significant validation of our system’s in-hospital potential and creates an incredible opportunity to integrate real-world surgeon experiences and feedback as we work toward our system’s finalization. These partnerships establish two powerful innovation conduits through which our team gains unprecedented access to understanding and addressing the complexities of surgical workflow and hospital integration while building commercial expertise. Meanwhile, our clinical partners – HCA Healthcare and University Hospitals – become the first health systems to access our minimally invasive surgical robot and directly influence its advancement. We could not be more excited to partner with two of the top institutions in the country as we progress on our path to improve surgery for patients, surgeons, hospitals, and payors.” Adam Sachs, CEO and co-founder of Vicarious Surgical “Our surgical and innovation teams are on the cutting edge of new care technologies designed to benefit patients,” said Dr. Joseph Sabik, Chairman, Department of Surgery at University Hospitals. “Collaborating with Vicarious Surgical on their Center of Excellence model for training and next generation surgical robotics provides our team a thrilling front row seat in the quest to improve the landscape for minimally-invasive surgery that enhances patient care and clinical outcomes.” “University Hospitals’ goal is to be the most trusted health care partner in Northeast Ohio,” explained Kendra Gardiner, Director of Product Strategy for UH Ventures. “As part of this strategy, UH is dedicated to accelerating discovery, innovation and translation of scientific breakthroughs that address unmet clinical and social needs to enhance the lives of our patients, our communities and the world. We also aim to be the partner of choice by creating and sharing value together. This new relationship with Vicarious Surgical is one example of how we are advancing this objective.” About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. HCA Healthcare subsidiary Health Insight Capital makes equity investments in early-stage companies that are selected to provide innovative solutions for use in health system operations and is an investor in Vicarious Surgical. Please click here to connect with HCA Healthcare on social media. About UH Ventures UH Ventures is the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with annual revenues in excess of $5.0 billion, more than 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. UH’s goal is to be the most trusted health care partner in Northeast Ohio and UH Ventures furthers this objective by shaping new products, services, experiences, and companies that improve the lives of patients and caregivers. To advance the UH mission, UH Ventures strives to support a diverse portfolio of value-adding opportunities in health care, enhance the distinct and unique capabilities of the system, and foster a culture of discovery, innovation, and entrepreneurship within UH and the larger community. For caregivers, UH Ventures provides the tools and resources needed to nurture, validate, and advance ideas sparked by day-to-day insights. For potential partners, UH Ventures seeks to be a dynamic living laboratory where both clinical and product insights can help accelerate emerging technologies tackling health care’s most pressing problems.

Read More

HEALTH TECHNOLOGY

Resolution Medical Completes Acquisition of LifeTec Group

Resolution Medical | June 10, 2022

Resolution Medical, a part of Arcline Investment Management and a leading medical device contract development and manufacturing firm, has announced the acquisition of LifeTec GroupTM. LifeTec is a Dutch firm and a premier pre-clinical contract research organization (CRO) globally. "LifeTec's biosimulation services and technologies add clinical insight depth and accelerate R&D execution for medical device companies around the world. We have long been impressed by the LifeTec team's capabilities, and are extremely excited to come together. Our customers look for fully integrated development and manufacturing capabilities, fast and agile execution, and clinically deep anatomical and physiological expertise. That is what Resolution Medical offers and embodies. LifeTec is a fantastic addition to further our mission of Partnering to Bring the Frontiers of Medical Technology to Life." Luke Johnson, CEO of Resolution Medical “Medical technology innovation is best achieved by integrating design, prototyping, pre-clinical verification and validation, and manufacturing. We've found an excellent partner in Resolution Medical to globally leverage the value we bring by combining our unparalleled pre-clinical services with their best-in-class development and manufacturing services. We're incredibly excited to join Resolution Medical and shape the future of accelerated medical technology innovation." Jurgen de Hart, CEO of LifeTec Johnson further commented, "Resolution Medical has just finished a new 35,000 sq. ft. dedicated R&D facility in Minneapolis, adjacent to our current facility, which will be fully dedicated to manufacturing. Within that new R&D facility we now have a state-of-the-art biosimulation lab that leverages LifeTec's multiple simulation platforms and many years of expertise. This lab includes ultrasound and fluoroscopy imaging, and we are excited to now begin offering this service to our customers at sites both in the U.S. and Europe."

Read More

HEALTH TECHNOLOGY

Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Matrix Medical Network | August 09, 2022

Matrix Medical Network® and Emvenio Research® announced the sale of the Matrix Clinical Trials service line to Emvenio, a leading decentralized clinical trials company. The transaction will provide Emvenio with proven DCT capabilities, while allowing Matrix to focus on improving the health and wellness of health plan members, and keeping America's workers productive and safe, through its design of custom and flexible clinical solutions. Post transaction, Emvenio will deploy additional resources, technology, and capital to continue to grow and scale its clinical trials services both domestically and internationally, making clinical research more accessible, equitable, and effective. "At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians, Mobile Health Clinics, and experienced leaders to adapt traditional clinical trials protocols to better reach and recruit diverse, underserved, and high-risk patients. We are incredibly proud of the remarkable work the Matrix Clinical Trials team started during the pandemic and continued to expand upon. I am excited about this transition and look forward to watching the leaders and employees of Emvenio continue to develop and deliver decentralized clinical trial solutions that best serve those patients who most need access to new treatments." Catherine J. Tabaka, Matrix Chief Executive Officer "The leaders of Matrix Clinical Trials showed leadership, agility, creativity, and perseverance in building a decentralized clinical trial organization from the ground up," said Keith Henthorne, Emvenio Chief Executive Officer. "I look forward to working closely with these leaders in order to build upon this solid foundation established by Matrix and to continue making clinical trials more accessible to diverse populations throughout the world. To ensure continued access to clinical trials for the patients who need it most, many Matrix employees and leaders will be a part of the Emvenio team going forward. I am proud to be working alongside strong leaders like Dr. Daniel Castillo and Thad Wolfram, amongst others, and look forward to growing the company with them." About Matrix Medical Network Matrix Medical Network has provided expert care and health services to millions of at-risk individuals where they live and work for more than 20 years. The organization's network of approximately 4,000 clinicians meets individuals wherever they are, to assess their health and safety, identify and close care gaps, and offer life-changing services that activate them to manage their own health. About Emvenio Emvenio is a leading decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Its mission is to eliminate the barriers to clinical trials by engaging with people in their communities and in their homes. Emvenio's technology enabled, innovative network of Mobile Research Sites, At Home Visits, and Virtual Visits are a unique blend of global DCT capabilities that can be deployed to better reach, recruit and retain diverse patient populations, while improving the clinical trial experience. These capabilities offer global DCT participant-centric approaches that provide flexibility, meet the most challenging clinical trial demands, and provide convenience for patients and caregivers in a compliant manner. Emvenio is transforming how all stakeholders engage in, experience, and deliver clinical research.

Read More